Time and cost advantage from R&D to industrialization: In the traditional model, the long-term cycle of pharmaceutical industrialization and the repeated investment of fixed assets seriously hinder the rapid transformation of innova¬tive achievements and products into the market. The Ruiying intelligent manufacturing platform can undertake more than 70% of the production of pharmaceuticals and intermediates, avoiding the fix-asset investment in the production line of a single product, thereby reducing the cycle of transforming innovative achievements into the "last mile" by more than 90% and saving 2/3 of the cost.

Industrialized manufacturing cost advantage brought by flexible manufacturing

Based on 30 years of pharmaceutical big data accumulation by Ruiying, we decomposed all phar¬maceutical modules into 109 standardized manufacturing units, and established process unit standardization I fragmentation and equipment unit standardization /modularity matching Model, through SCADA, MES and big data decision-making to achieve "multi-variety collinearity". The rent is charged according to the amount of platform resources and days occupied by the variety, and the power cost is measured according to the actual occurrence. Therefore, the varieties produced on the platform have the advantages of asset-light investment and low cost.

The synergistic competitive advantage of "industry chain integration": the platform has the manufacturing capacity of the whole industry chain, forms a complete industrial ecology, and can form a collaborative competitive advantage.

Advantages of multi-port cooperation: The units of the platform are inde¬-pendent and strategically coordinated, and can provide full life cycle services for clinical product CDMO, industrialized COMO and MAH holders.